From September 1993 through March 1994, 30 cases of refractory carcinoma of the ovary and Fallopian tube were treated with Taxol. Complete response was seen in 4 and partial response in 8 cases with a response rate o...From September 1993 through March 1994, 30 cases of refractory carcinoma of the ovary and Fallopian tube were treated with Taxol. Complete response was seen in 4 and partial response in 8 cases with a response rate of 40 %. The average length of remission was 5 months in CR and 3.9 months in PR. The major toxic side effect was decrease in total white cell count and in neutrophil count. Apart from flushing of face during Taxol infusion in 6 patients, no other allergic reaction was observed. Gastrointestinal, neurologic, liver and renal toxicities were mild. Taxol is a drug of choice in the treatment of patients with cancer of the ovary and Fallopian tube who are resistant to conventional chemotherapy.展开更多
Objective:The aim of this study was to compare the efficacies and safeties of the combination of docetaxelcarboplatin with the combination of non docetaxel-carboplatin as first-line chemotherapy for advanced epithelia...Objective:The aim of this study was to compare the efficacies and safeties of the combination of docetaxelcarboplatin with the combination of non docetaxel-carboplatin as first-line chemotherapy for advanced epithelial ovarian,primary peritoneal or fallopian tube cancers.Methods:Relevant articles were identified from MEDLINE(1993-2010),EMBASE(1980-2010),MEDION,the Cochrane library,Science Citation Index Expanded databases,hand searching of reference lists from primary articles and reviews,conference abstracts and contact with experts in the field.The review included 5 relevant primary studies(1430 women).Data was extracted for study characteristics and quality.Bivariate random-effect model metaanalysis was used to estimate diagnostic accuracy of the various index tests.A quantitative meta-analysis was carried out by two reviewers based on the inclusion criteria from all available studies.Results:The frequency of the subgroup analysis of toxicity showed that toxicity action of combination of docetaxel-carboplatin was more severe than that of non docetaxelcarboplatin group(OR = 1.33,95% CI = 1.13-1.56,P = 0.0005),whereas that of clinical responses was equivalent in comparison combination of docetaxel-carboplatin with combination of paclitaxel-carboplatin or docetaxel-cisplatin(OR = 1.0,95% CI = 0.87-1.16,P = 0.95).There were heterogeneity(χ2 = 79.36,P < 0.00001) and inconsistency(83.6%) in toxicity analysis among the trials,while neither heterogeneity(χ2 = 3.21,P = 0.99) nor inconsistency(I2 = 0%) in clinical responses among the trials.Conclusion:The safety of combination of docetaxel-carboplatin is less than that of combination of paclitaxelcarboplatin or docetaxel-cisplatin.However,the clinical responses of combination of docetaxel-carboplatin are comparable with combination of paclitaxel-carboplatin or docetaxel-cisplatin.展开更多
近日,美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)公布了《2024 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》。新版指南在卵巢癌化疗、靶向治疗、基因检测等方面有重要更新。现对新版指南进行...近日,美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)公布了《2024 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》。新版指南在卵巢癌化疗、靶向治疗、基因检测等方面有重要更新。现对新版指南进行简要解读。展开更多
卵巢恶性肿瘤是妇科三大恶性肿瘤之一,其发病率较低,但死亡率较高,并且近20年死亡率仍然处于升高趋势。卵巢癌常呈现出频繁复发需多程化疗的特点,目前美国国立综合癌症网络(National Comprehensive Cancer Network, NCCN)指南已有针对...卵巢恶性肿瘤是妇科三大恶性肿瘤之一,其发病率较低,但死亡率较高,并且近20年死亡率仍然处于升高趋势。卵巢癌常呈现出频繁复发需多程化疗的特点,目前美国国立综合癌症网络(National Comprehensive Cancer Network, NCCN)指南已有针对各阶段卵巢癌的化疗方案推荐,但是同级别推荐的不同化疗方案如何选择仍不明确。鉴于此,NCCN于2015年发布带有证据块的NCCN指南,其从E.方案/药物的疗效;S.方案/药物的安全性;Q.证据质量;C.证据的一致性;A.方案/药物的可负担性,5个维度对不同化疗方案进行比较,以便根据患者不同病情及个人状况选择更合适的化疗方案,从而实现个体化、精准化治疗。展开更多
近日,美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)公布了《2023 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》。新版指南在卵巢癌化疗、靶向治疗、基因检测等方面有重要更新。现对新版指南进行...近日,美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)公布了《2023 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》。新版指南在卵巢癌化疗、靶向治疗、基因检测等方面有重要更新。现对新版指南进行简要解读。12023年指南主要更新(1)新增推荐保留生育功能患者术前进行生殖内分泌与不孕症评估、必要时行子宫内膜活检。(2)一线PARP抑制剂维持治疗更新:①一线维持治疗新增卢卡帕利;②贝伐珠单抗+奥拉帕利维持治疗改为1类推荐;③BRCA突变、化疗联合贝伐珠单抗患者,停化疗后推荐奥拉帕利+贝伐珠单抗(1类)维持治疗,也可以使用PARP抑制剂单药维持治疗;④化疗联合贝伐珠单抗的同源重组修复缺陷(HRD)患者,也可以选择贝伐珠单抗维持治疗。展开更多
近日,美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)公布了《2022 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》。新版指南在卵巢癌化疗、基因检测等方面有重要更新。现对新版指南进行简要解读。1...近日,美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)公布了《2022 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》。新版指南在卵巢癌化疗、基因检测等方面有重要更新。现对新版指南进行简要解读。1新版指南主要更新(1)ⅠB、ⅠC1期卵巢透明细胞癌全面分期手术后可以考虑观察或化疗。(2)新增低级别浆液性癌治疗后监测和继续治疗的流程。(3)推荐采用有效的评分手段评估是否进行二次肿瘤细胞减灭术。展开更多
文摘From September 1993 through March 1994, 30 cases of refractory carcinoma of the ovary and Fallopian tube were treated with Taxol. Complete response was seen in 4 and partial response in 8 cases with a response rate of 40 %. The average length of remission was 5 months in CR and 3.9 months in PR. The major toxic side effect was decrease in total white cell count and in neutrophil count. Apart from flushing of face during Taxol infusion in 6 patients, no other allergic reaction was observed. Gastrointestinal, neurologic, liver and renal toxicities were mild. Taxol is a drug of choice in the treatment of patients with cancer of the ovary and Fallopian tube who are resistant to conventional chemotherapy.
文摘Objective:The aim of this study was to compare the efficacies and safeties of the combination of docetaxelcarboplatin with the combination of non docetaxel-carboplatin as first-line chemotherapy for advanced epithelial ovarian,primary peritoneal or fallopian tube cancers.Methods:Relevant articles were identified from MEDLINE(1993-2010),EMBASE(1980-2010),MEDION,the Cochrane library,Science Citation Index Expanded databases,hand searching of reference lists from primary articles and reviews,conference abstracts and contact with experts in the field.The review included 5 relevant primary studies(1430 women).Data was extracted for study characteristics and quality.Bivariate random-effect model metaanalysis was used to estimate diagnostic accuracy of the various index tests.A quantitative meta-analysis was carried out by two reviewers based on the inclusion criteria from all available studies.Results:The frequency of the subgroup analysis of toxicity showed that toxicity action of combination of docetaxel-carboplatin was more severe than that of non docetaxelcarboplatin group(OR = 1.33,95% CI = 1.13-1.56,P = 0.0005),whereas that of clinical responses was equivalent in comparison combination of docetaxel-carboplatin with combination of paclitaxel-carboplatin or docetaxel-cisplatin(OR = 1.0,95% CI = 0.87-1.16,P = 0.95).There were heterogeneity(χ2 = 79.36,P < 0.00001) and inconsistency(83.6%) in toxicity analysis among the trials,while neither heterogeneity(χ2 = 3.21,P = 0.99) nor inconsistency(I2 = 0%) in clinical responses among the trials.Conclusion:The safety of combination of docetaxel-carboplatin is less than that of combination of paclitaxelcarboplatin or docetaxel-cisplatin.However,the clinical responses of combination of docetaxel-carboplatin are comparable with combination of paclitaxel-carboplatin or docetaxel-cisplatin.
文摘卵巢恶性肿瘤是妇科三大恶性肿瘤之一,其发病率较低,但死亡率较高,并且近20年死亡率仍然处于升高趋势。卵巢癌常呈现出频繁复发需多程化疗的特点,目前美国国立综合癌症网络(National Comprehensive Cancer Network, NCCN)指南已有针对各阶段卵巢癌的化疗方案推荐,但是同级别推荐的不同化疗方案如何选择仍不明确。鉴于此,NCCN于2015年发布带有证据块的NCCN指南,其从E.方案/药物的疗效;S.方案/药物的安全性;Q.证据质量;C.证据的一致性;A.方案/药物的可负担性,5个维度对不同化疗方案进行比较,以便根据患者不同病情及个人状况选择更合适的化疗方案,从而实现个体化、精准化治疗。
文摘近日,美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)公布了《2023 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》。新版指南在卵巢癌化疗、靶向治疗、基因检测等方面有重要更新。现对新版指南进行简要解读。12023年指南主要更新(1)新增推荐保留生育功能患者术前进行生殖内分泌与不孕症评估、必要时行子宫内膜活检。(2)一线PARP抑制剂维持治疗更新:①一线维持治疗新增卢卡帕利;②贝伐珠单抗+奥拉帕利维持治疗改为1类推荐;③BRCA突变、化疗联合贝伐珠单抗患者,停化疗后推荐奥拉帕利+贝伐珠单抗(1类)维持治疗,也可以使用PARP抑制剂单药维持治疗;④化疗联合贝伐珠单抗的同源重组修复缺陷(HRD)患者,也可以选择贝伐珠单抗维持治疗。
文摘近日,美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)公布了《2022 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》。新版指南在卵巢癌化疗、基因检测等方面有重要更新。现对新版指南进行简要解读。1新版指南主要更新(1)ⅠB、ⅠC1期卵巢透明细胞癌全面分期手术后可以考虑观察或化疗。(2)新增低级别浆液性癌治疗后监测和继续治疗的流程。(3)推荐采用有效的评分手段评估是否进行二次肿瘤细胞减灭术。
